Rugo and colleagues conducted the SOPHIA trial, a multinational, open‐label, randomized phase 3 study to compare the clinical effectiveness of margetuximab versus trastuzumab in patients with HER2‐positive ABC after progression on two or more lines of HER2‐directed therapies and at least one non‐hormonal therapy for metastatic cancer. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm.